HROW-117 (AR-117)
Allergic Conjunctivitis
Phase 2Active
Key Facts
About Harrow Health
Harrow Health is an integrated eyecare company with a mission to address unmet needs in ophthalmology through a diversified business model encompassing proprietary pharmaceuticals, non-sterile compounding, and sterile compounding. The company has achieved commercial success with several FDA-approved products and maintains a pipeline of development-stage candidates. Its strategic direction involves leveraging its ImprimisRx platform for distribution while advancing its proprietary pipeline through internal development and acquisitions.
View full company profileTherapeutic Areas
Other Allergic Conjunctivitis Drugs
| Drug | Company | Phase |
|---|---|---|
| Alesion® (epinastine) | Santen Pharmaceutical | Approved |
| Reproxalap | Aldeyra Therapeutics | Phase 3 |